Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has earned an average recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.60.

A number of research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Monday, April 21st. HC Wainwright lowered their price target on Phathom Pharmaceuticals from $28.00 to $20.00 and set a "buy" rating for the company in a research report on Friday. Cantor Fitzgerald raised Phathom Pharmaceuticals to a "strong-buy" rating in a report on Tuesday, February 25th. Craig Hallum reaffirmed a "buy" rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. Finally, The Goldman Sachs Group cut their price target on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday.

Phathom Pharmaceuticals Price Performance

NASDAQ PHAT traded down $0.60 during trading on Tuesday, hitting $2.76. The company's stock had a trading volume of 4,676,435 shares, compared to its average volume of 1,066,073. Phathom Pharmaceuticals has a fifty-two week low of $2.71 and a fifty-two week high of $19.71. The company has a market cap of $192.23 million, a PE ratio of -0.49 and a beta of 0.15. The business's 50 day simple moving average is $4.96 and its 200-day simple moving average is $7.70.

Institutional Trading of Phathom Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company's stock worth $29,000 after acquiring an additional 4,050 shares in the last quarter. CWM LLC boosted its position in Phathom Pharmaceuticals by 20,997.1% during the first quarter. CWM LLC now owns 7,384 shares of the company's stock worth $46,000 after purchasing an additional 7,349 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Phathom Pharmaceuticals in the fourth quarter valued at approximately $74,000. Teacher Retirement System of Texas purchased a new stake in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $90,000. Finally, Rafferty Asset Management LLC acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at $90,000. Institutional investors and hedge funds own 99.01% of the company's stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.